Sugi Predict

Sugi Predict / Compounds / SCHEMBL2134574

SCHEMBL2134574

SCHEMBL2134574

CC(C)(C)OC(=O)N1C(=O)C2C=CC1C2

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ CHRM3 P20309 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ NR1H2 P55055 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ HSD11B1 P28845 2/20 0.34
▸ GPR119 Q8TDV5 1/20 0.33
▸ ELANE P08246 1/20 0.33
▸ STS P08842 1/20 0.33
▸ AR P10275 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ KLK7 P49862 1/20 0.33
▸ BUB1 O43683 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23583803 1.00 CHRM2 (0.37) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL2134581 1.00 CHRM2 (0.37) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL12392946 1.00 CHRM2 (0.37) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL782700 1.00 CHRM2 (0.37) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL15986600 0.80 ELANE (0.36) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL15933110 0.80 ELANE (0.36) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL6822290 0.79 ALDH1A1 (0.40) KDM4EMAPTTHRBNFKB1NFKB2
SCHEMBL6818549 0.79 ALDH1A1 (0.40) KDM4EMAPTTHRBNFKB1NFKB2
SCHEMBL15933104 0.78 KDM4E (0.36) CHRM2CHRM1CHRM3KDM4EMAPT
SCHEMBL6824552 0.76 MAPK1 (0.36) ELANEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025045777-A1 INHIBITORS OF PCSK9 DRAUPNIR BIO APS (DK) 2025-03-06 — — WO disclosed
US-12173026-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-12-24 — — US disclosed
US-20230062119-A1 USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR MERCK SHARP & DOHME LLC (US) 2023-03-02 — — US disclosed
US-20220363707-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-11-17 — — US disclosed
EP-3930697-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY Praxis Biotech LLC (US) 2022-01-05 — — EP disclosed
US-20200270232-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2020-08-27 — — US disclosed
US-20200270232-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2020-08-27 — — US disclosed
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2018-10-11 — — US disclosed
US-20170267657-A1 PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO DOW AGROSCIENCES LLC (US) 2017-09-21 — — US disclosed
US-9718788-B2 Heteroaryl compounds useful as inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-08-01 — — US disclosed
WO-2006035967-A1 PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 — — WO disclosed
US-6630477-B1 Therapeutic nucleoside compound SMITHKLINE BEECHAM CORPORATION 2003-10-07 — — US disclosed
EP-1150988-B1 PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS GLAXO GROUP LTD (GB) 2003-05-28 — — EP disclosed
EP-1150981-B1 USE OF (1R, 4S)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL IN HBV GLAXO GROUP LTD (GB) 2003-04-16 — — EP disclosed
EP-1235834-A1 (1R,CIS)-4-(4-AMINO-7H-PYRR0L0[2,3- I(D)]PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL GLAXO GROUP LIMITED (GB) 2002-09-04 — — EP disclosed
EP-1150988-A1 PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS GLAXO GROUP LIMITED (GB) 2001-11-07 — — EP disclosed
EP-1150981-A1 THERAPEUTIC NUCLEOSIDE COMPOUND GLAXO GROUP LIMITED (GB) 2001-11-07 — — EP disclosed
WO-2001042255-A1 (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL GLAXO GROUP LIMITED (GB) 2001-06-14 — — WO disclosed
WO-2000047581-A1 THERAPEUTIC NUCLEOSIDE COMPOUND GLAXO GROUP LIMITED (GB) 2000-08-17 — — WO disclosed
WO-2000047591-A1 PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS GLAXO GROUP LIMITED (GB) 2000-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220363707-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 CHRM2 4790/4885CHRM1 4556/4885CHRM3 4759/4885
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 CHRM2 3707/4885CHRM1 3321/4885CHRM3 3708/4885
US-12173026-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 CHRM2 4790/4885CHRM1 4556/4885CHRM3 4759/4885
US-20200270232-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 CHRM2 4741/4885CHRM1 4819/4885CHRM3 4571/4885
US-20170267657-A1 PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO ACHE, DDT, PTMS CHRM2 673/4885CHRM1 1301/4885CHRM3 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.